VIVUS Press Releases

Date Title Links
Toggle Summary VIVUS Reports Third Quarter 2017 Financial Results
CAMPBELL, CA -- (Marketwired) -- 11/07/17 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results for
View HTML
Toggle Summary VIVUS Completes Tacrolimus Pre-IND Meeting With FDA
Company on track to initiate clinical trials in 2018
View HTML
Toggle Summary VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Tuesday, November 7, 2017
CAMPBELL, CA -- (Marketwired) -- 10/31/17 -- VIVUS, Inc. (NASDAQ: VVUS) today announced that it will report financial results and provide a business update for the third quarter of 2017 after the market close on Tuesday, November 7, 2017 . The company will host a conference call beginning at 4:30
View HTML
Toggle Summary VIVUS Announces Tacrolimus Receives Orphan Drug Designation in the European Union for the Treatment of Pulmonary Arterial Hypertension
CAMPBELL, CA -- (Marketwired) -- 09/06/17 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that the European
View HTML
Toggle Summary VIVUS and Alvogen Announce Marketing Agreement for Qsymia(R) in the Republic of Korea
CAMPBELL, CA , and SAN GWANN, MALTA -- (Marketwired) -- 09/05/17 -- VIVUS, Inc. (NASDAQ: VVUS) and Alvogen Malta Operations (ROW) Ltd , today announced an agreement under which Alvogen will market Qsymia ® (phentermine and topiramate extended-release) in the Republic of Korea for the treatment of
View HTML
Toggle Summary VIVUS Announces Settlement with Dr. Reddy's Laboratories on Qsymia(R) Patent Litigation
CAMPBELL, CA -- (Marketwired) -- 08/30/17 -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Dr. Reddy's Laboratories, S.A. and Dr. Reddy's Laboratories, Inc. (Dr. Reddy's) resolving patent litigation related to Qsymia® (phentermine and topiramate
View HTML
Toggle Summary VIVUS to Present at 2017 Wells Fargo Healthcare Conference on September 7, 2017
CAMPBELL, CA -- (Marketwired) -- 08/22/17 -- VIVUS,Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today announced that Seth H. Z.
View HTML
Toggle Summary VIVUS Reports Second Quarter 2017 Financial Results
  CAMPBELL, CA -- (Marketwired) -- 08/03/17 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), a biopharmaceutical company committed to the development and commercialization of innovative therapies focusing on treatments for patients with serious unmet medical needs, today reported financial results
View HTML
Toggle Summary VIVUS Announces Settlement with Actavis on Qsymia(R) Patent Litigation
CAMPBELL, CA -- (Marketwired) -- 07/05/17 -- VIVUS, Inc. (NASDAQ: VVUS) announced today that it has entered into a settlement agreement with Actavis Laboratories FL (Actavis) resolving patent litigation related to Qsymia® (phentermine and topiramate extended-release) capsules CIV.
View HTML
Toggle Summary Thomas B. King Joins VIVUS' Board of Directors
CAMPBELL, CA -- (Marketwired) -- 05/24/17 -- VIVUS, Inc. (NASDAQ: VVUS) (the "Company"), announced today that Thomas B. King has been appointed to VIVUS' board of directors. Mr. King's nearly 40 years of pharmaceutical experience ranges from large to development-stage pharmaceutical companies.
View HTML